Crinetics Pharmaceuticals has submitted a Marketing Authorization Application to Brazil's ANVISA for Palsonify (paltusotine), an oral once-daily treatment for acromegaly in adults. This submission follows positive results from two Phase 3 trials showing effective biochemical and symptom control. Palsonify is already approved in the US and has received a positive opinion in Europe, marking a key step for global expansion. The company now awaits regulatory review in Brazil to potentially offer a new oral treatment option for acromegaly patients there.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Prologis reported strong second quarter results with net earnings per share rising to $1.13 from $0.61 in 2025, driven by record leasing of over 67 million square feet and increased occupancy to 95.5%. The company raised its 2026 earnings guidance fo...
IQSTEL Inc. announced preliminary net revenue of approximately $207 million for the first half of 2026, marking a 59% increase from $130 million in the same period of 2025. The company expects to complete its acquisition of Ultranet this quarter, whi...
The XRP Ledger has surpassed 8 million activated accounts, signaling increased global adoption for sending and managing blockchain assets. This milestone coincides with whale wallets accumulating 70 million XRP in the past week, indicating strong dem...
